India has ramped up its coronavirus vaccine production and approved Johnson & Johnson's single-dose vaccine for emergency use amid warnings of a third wave. The vaccine, with 85% efficacy, will be introduced through a supply agreement with homegrown vaccine maker Biological E. It is still unclear when the vaccine will be available. Daily case counts have fallen from 400,000, but they still average up to 40,000, and experts have warned that a third wave of infections is inevitable. Johnson & Johnson's jab is the second foreign vaccine to be granted emergency use authorisation under a new policy not requiring manufacturers to conduct local clinical trials if the vaccine is approved by WHO. In June the Moderna vaccine was given Indian approval, but the company is locked in a legal tussle, and no one has yet been given Immunisation.